You are here: Home » Companies » News
Business Standard

Glenmark Pharma gets USFDA approval for prostate cancer treatment drug

The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech

Glenmark Pharma | Glenmark Pharmaceuticals

Press Trust of India  |  New Delhi 

Glenmark Pharmaceuticals

Drug firm on Thursday said it has received final approval from the US health regulator for Abiraterone Acetate tablets, used to treat prostate cancer.

The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech.

"Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Abiraterone Acetate tablets USP, 250 mg," the company said in a regulatory filing.

Quoting IQVIA sales data for the 12 month period ending August 2019, Glenmark said the Zytiga tablets, 250 mg market achieved annual sales of approximately $794.1 million.

Glenmark's current portfolio consists of 162 products authorised for distribution in the US marketplace and 46 ANDA's pending approval with the USFDA.

Shares of were trading 0.15 per cent higher at Rs 286.00 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 17 2019. 11:15 IST